IN-1233, an ALK-5 inhibitor: Prevention of granulation tissue formation after bare metallic stent placement in a rat urethral model

Radiology

Volumn 255, Issue 1, 2010, Pages 75-82

  Kim, Jin Hyoung ^a   Song, Ho Young ^a   Park, Jung Hoon ^a   Yoon, Hyun Jung ^a   Park, Hyung Gyu ^a   Kim, Dae Kee ^b  

^a University of Ulsan College of Medicine   (South Korea)

^b Ewha Womans University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

3 [[4 (6 METHYLPYRIDIN 2 YL) 5 (QUINOLIN 6 YL) 1H IMIDAZOL 2 YL]METHYL]BENZAMIDE; CYTOKINE RECEPTOR ANTAGONIST; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BARE METAL STENT; CELL INFILTRATION; CONTROLLED STUDY; FLUOROSCOPY; FOLLOW UP; GRANULATION TISSUE; INFLAMMATORY CELL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; URETHRA; URETHROGRAPHY;

ANIMALS; BENZAMIDES; GRANULATION TISSUE; HYPERPLASIA; MALE; METALS; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; STATISTICS, NONPARAMETRIC; STENTS; URETHRA;

EID: 77950415363     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.09090670     Document Type: Article

References (32)

1. Orons PD, Amesur NB, Dauber JH, Zajko AB, Keenan RJ, Iacono AT. Balloon dilation and endobronchial stent placement for bronchial strictures after lung transplantation. J Vasc Interv Radiol 2000;11(1):89-99.
2. Song HY, Park HK, Suh TS, et al. Recurrent traumatic urethral strictures near the external sphincter: treatment with a covered, retrievable, expandable nitinol stent - initial results. Radiology 2003;226(2):433-440.
3. Holm AN, de la Mora Levy JG, Gostout CJ, Topazian MD, Baron TH. Self-expanding plastic stents in treatment of benign esophageal conditions. Gastrointest Endosc 2008;67(1):20-25.
4. Kennedy AS, Sonett JR, Orens JB, King K. High dose rate brachytherapy to prevent recurrent benign hyperplasia in lung transplant bronchi: theoretical and clinical considerations. J Heart Lung Transplant 2000;19(2):155-159.
5. Karagiannidis C, Velehorschi V, Obertrifter B, Macha HN, Linder A, Freitag L. High-level expression of matrix-associated transforming growth factor-beta1 in benign airway stenosis. Chest 2006;129(5):1298-1304.
6. Liu W, Wang DR, Cao YL. TGF-beta: a fibrotic factor in wound scarring and a potential target for anti-scarring gene therapy. Curr Gene Ther 2004;4(1):123-136.
7. Long L, Crosby A, Yang X, et al. Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease. Circulation 2009;119(4):566-576.
8. Ko GY, Kim GC, Seo TS, et al. Covered, retrievable, expandable urethral nitinol stent: feasibility study in dogs. Radiology 2002;223(1):83-90.
9. Shin JH, Song HY, Choi CG, et al. Tissue hyperplasia: influence of a paclitaxel-eluting covered stent - preliminary study in a canine urethral model. Radiology 2005;234(2):438-444.
10. Teirstein PS, Massullo V, Jani S, et al. Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med 1997;336(24):1697-1703.
11. Kim JH, Shin JH, Song HY, Shim TS, Yoon CJ, Ko GY. Benign tracheobronchial strictures: long-term results and factors affecting airway patency after temporary stent placement. AJR Am J Roentgenol 2007;188(4):1033-1038.
12. Cwikiel W, Willén R, Stridbeck H, Lillo-Gil R, von Holstein CS. Self-expanding stent in the treatment of benign esophageal strictures: experimental study in pigs and presentation of clinical cases. Radiology 1993;187(3):667-671.
13. Dick P, Sabeti S, Mlekusch W, et al. Conventional balloon angioplasty versus peripheral cutting balloon angioplasty for treatment of femoropopliteal artery instent restenosis: initial experience. Radiology 2008;248(1):297-302.
14. Kim JH, Shin JH, Song HY, et al. Liquid (188)Re-filled balloon dilation for the treatment of refractory benign airway strictures: preliminary experience. J Vasc Interv Radiol 2008;19(3):406-411.
15. Branton MH, Kopp JB. TGF-beta and fibrosis. Microbes Infect 1999;1(15):1349-1365.
16. Imai E, Isaka Y, Fujiwara Y, Kaneda Y, Kamada T, Ueda N. Introduction of a foreign gene into the kidney in vivo: development of glomerulosclerosis by the transfection of genes for PDGF and TGF-beta. Contrib Nephrol 1994;107:205-215.
17. Kopp JB, Factor VM, Mozes M, et al. Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. Lab Invest 1996;74(6):991-1003.
18. Sime PJ, Xing Z, Graham FL, Csaky KG, Gauldie J. Adenovector-mediated gene transfer of active transforming growth factorbeta1 induces prolonged severe fibrosis in rat lung. J Clin Invest 1997;100(4):768-776.
19. Sanderson N, Factor V, Nagy P, et al. Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci U S A 1995;92(7):2572-2576.
20. Giri SN, Hyde DM, Braun RK, Gaarde W, Harper JR, Pierschbacher MD. Antifibrotic effect of decorin in a bleomycin hamster model of lung fibrosis. Biochem Pharmacol 1997;54(11):1205-1216.
21. Zhao J, Sime PJ, Bringas P Jr, Gauldie J, Warburton D. Adenovirus-mediated decorin gene transfer prevents TGF-beta-induced inhibition of lung morphogenesis. Am J Physiol 1999;277(2 pt 1):L412-L422.
22. Yata Y, Gotwals P, Koteliansky V, Rockey DC. Dose-dependent inhibition of hepatic fibrosis in mice by a TGF-beta soluble receptor: implications for antifibrotic therapy. Hepatology 2002;35(5):1022-1030.
23. Wang Q, Wang Y, Hyde DM, et al. Reduction of bleomycin induced lung fibrosis by transforming growth factor beta soluble receptor in hamsters. Thorax 1999;54(9):805-812.
24. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature 1990;346(6282):371-374.
25. Miyajima A, Chen J, Lawrence C, et al. Antibody to transforming growth factor-beta ameliorates tubular apoptosis in unilateral ureteral obstruction. Kidney Int 2000;58(6):2301-2313.
26. Giri SN, Hyde DM, Hollinger MA. Effect of antibody to transforming growth factor beta on bleomycin induced accumulation of lung collagen in mice. Thorax 1993;48(10):959-966.
27. Grygielko ET, Martin WM, Tweed C, et al. Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type-I receptor kinase in puromycin-induced nephritis. J Pharmacol Exp Ther 2005;313(3):943-951.
28. Bonniaud P, Margetts PJ, Kolb M, et al. Progressive transforming growth factor beta1-induced lung fibrosis is blocked by an orally active ALK-5 kinase inhibitor. Am J Respir Crit Care Med 2005;171(8):889-898.
29. de Gouville AC, Boullay V, Krysa G, et al. Inhibition of TGF-beta signaling by an ALK-5 inhibitor protects rats from dimethylnitrosamine-induced liver fibrosis. Br J Pharmacol 2005;145(2):166-177.
30. Moon JA, Kim HT, Cho IS, Sheen YY, Kim DK. IN-1130, a novel transforming growth factor-beta type-I receptor kinase (ALK-5) inhibitor, suppresses renal fibrosis in obstructive nephropathy. Kidney Int 2006;70(7):1234-1243.
31. Luo J, Ho PP, Buckwalter MS, et al. Glia-dependent TGF-beta signaling, acting independently of the TH17 pathway, is critical for initiation of murine autoimmune encephalomyelitis. J Clin Invest 2007;117(11):3306-3315.
32. Kim YW, Kim YK, Lee JY, et al. Pharmacokinetics and tissue distribution of 3-((5-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)-1-H-imidazol-2-yl)methyl) benzamide; a novel ALK-5 inhibitor and a potential anti-fibrosis drug. Xenobiotica 2008;38(3):325-339.